Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Cibus Global LLC (CBUS)

Healthcare Biotechnology
1.90 $
+0.0% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Cibus Global LLC.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 2 of our scanner strategies — each hit links to the scanner.

Momentum & Trend

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Basics

Market Cap
0.2$B
Shares Outstanding
76Mio.
Float
74.9%
Beta
1.7

Performance

Perf. 1M
-1.40%
Perf. 3M
-23.90%
Perf. 6M
-18.30%
YTD Performance (%)
-21.30%
52-Week-High Distance
-68.0%
Perf. 1Y
-9.27%
Perf. 3Y
-89.80%
Perf. 5Y
-99.34%

Valuation

P/E
Forward P/E
0.0
PEG
P/B
4.2
P/S
35.6
EV/EBITDA
-1.1
Price/FCF

Profitability

Gross Margin
100.0%
EBIT Margin
Net Margin
0.0%
Return on Equity
-190.1%
Return on Assets
-11.2%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
7.8
warning zone
Altman Z″
-6.48
Piotroski
6 out of 9

Growth

Sales Growth Last Quarter
62.60%
EPS Growth Last Quarter
0.00%
Sales Growth (Year)
-14.62%
Forward Sales Growth
77.57%
Forward EPS Growth
13.10%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
4
RS Rating
12
EPS Rating
42
Piotroski
6 out of 9
Fundamental Rating
C (49 out of 100)
warning zone
Altman Z″
-6.48

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 1.90 $
Price Target (average) 14.67 $

The price target sits 672.1% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

13. Aug 2026 · after the close · Q2 2026
Expected Earnings per Share
-0.26 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 1.2 $M Q4 2025: Q1 · 1.0 $M Q1 2025: Q2 · 0.9 $M Q2 2025: Q3 · 0.6 $M Q3 2025: Q4 · 1.1 $M Q4 2026: Q1 · 1.7 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.30 1 9.90 -1,906.10 -14 -14
2025: Q1 -0.61 1 89.70 -4,534.40 -12 -12
2025: Q2 -0.33 1 11.30 -2,719.40 -14 -14
2025: Q3 -0.31 1 -63.10 -3,827.80 -12 -12
2025: Q4 -0.41 1 -12.80 -2,959.90 -13 -14
2026: Q1 -0.28 2 62.60 -1,262.50 -12 -12
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Cibus, Inc. ist ein Agrar-Biotechnologieunternehmen, das gen-editierte Pflanzeneigenschaften entwickelt und lizenziert.

Employees118
HeadquartersSan Diego, CA
Websitecibus.com
IPO Date1. Jun 2023

Management

Management
Name Title Birth Year
Craig Wichner Chief Executive Officer 1970
Peter R. Beetham B.Sc., Ph.D. Co-Founder, President & COO 1963
Gregory F. Gocal Ph.D. Co-Founder, Chief Scientific Officer & Executive VP 1969
Rory Balfour Riggs M.B.A. Co-Founder & Director 1953
Jason Stokes Esq., J.D. Chief Administrative Officer, General Counsel & Corporate Secretary 1971
Cornelis Broos M.Sc. Chief Financial Officer 1972
Rosa Cheuk Kim J.D. Senior Vice President of Legal
Noel Sauer Ph.D. Senior Vice President of Research 1967

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?